PTEN and non-small cell lung carcinoma: The recently published BASALT-1 study on buparlisib alone in a cohort of NSCLC patients with aberrant activation of the PI3K pathway (PI3K or PTEN point mutations and loss of PTEN expression) showed that this drug did not elicit relevant clinical effects [23].